Acutaas Chemicals Ltd

- No explicit mention of any new fundraising through debt or equity in the current call. - Capex plans detailed: INR 250 crores for FY '26, primarily growth capex (INR 210 crores) and maintenance capex (INR 40 crores). - FY '27 and FY '28 capex expected to be mostly maintenance capex; no new major capex announced beyond current plans. - No stated plans for additional fundraising; focus is on utilizing existing resources for ongoing projects like electrolyte additives plant and South Korea JV. - Business expansion appears funded through internal accruals and existing investments, as no queries or responses indicate fresh fund raises.

- FY '26 capex planned around INR 250 crores, with INR 40 crores for maintenance and the rest for growth. - Major growth capex includes INR 180 crores for electrolyte additive plant at Jaghadia and INR 30 crores for pilot plant at Sachin. - Electrolyte additive capex expected to complete by Q4 FY '26 and start contributing from Q4 FY '26, fully ramping by FY '27. - South Korea JV (Indichem) capex underway, commercial production expected in H2 FY '27; Acutaas holds 75% stake. - Beyond FY '26, all planned growth capex expected to be completed; future capex to be mainly maintenance. - Additional capacity expansion in electrolyte additives possible depending on business development but no announcements yet. - Asset turnover target from capex approximately 2.5x over about 3 years.

- The company targets a 25% revenue growth for the full year FY '26, maintaining confidence despite achieving 21% growth in H1 FY '26. - Higher growth is expected from the CDMO business segment compared to traditional Pharma Intermediates. - Electrolyte additives segment is expected to start contributing from Q4 FY '26 and more significantly in FY '27, with full visibility on capex and products. - Semiconductor JV in South Korea is projected to start commercial production in H2 FY '27, contributing to revenue thereafter. - Specialty Chemicals segment is expected to grow around 10-15% in FY '26. - No specific revenue disclosure for new segments, but significant growth drivers identified in CDMO, battery chemicals, and semiconductor chemicals in the coming years. - Growth is supported by expanding product portfolio focusing on higher-margin products for sustainable growth. - Capacity ramp-up, especially Block 3 and new plants, expected to enhance volumes gradually over 2-3 years.

- The company expects sustainable EBITDA margins of 28% to 30% in FY '26 and beyond, driven by improved product mix, higher contribution from CDMO business, and operational efficiencies (Page 14). - Revenue growth guidance is maintained at around 25% for FY '26, backed by a robust CDMO pipeline, pharmaceutical intermediates, and new verticals like electrolyte additives and semiconductor chemicals (Pages 6, 12, 14). - New CDMO products are expected to start contributing by end of FY '26, post regulatory approvals (Page 6). - Electrolyte additive plant commissioning by Q4 FY '26 and full commercial contribution expected in FY '27, with South Korea JV beginning production in H2 FY '27 (Pages 7, 14, 15). - Operational improvements and solar plant contribution are expected to support margin and profit growth (Page 6). - Capital expenditures focused on growth (INR 210 crores approx. in FY '26) with asset turns around 2.5x and payback periods of 3-3.5 years, supporting medium-term earnings expansion (Pages 11, 14).

- Validation batches for new CDMO contracts have been sent during the quarter. - Commercial production for these new CDMO products is expected to start by the last quarter of FY '26, subject to regulatory approvals. - Full visibility exists for the CDMO business for the current year and projections for the next years, indicating a healthy order book. - The Block 3 at Ankleshwar, commissioned last year, is operational and catering to projected customer requirements. - For electrolyte additives, the planned capacity (2,000 metric tons each for VC and FEC) is based on signed contracts, providing full visibility on demand. - Overall, multiple products and customers across segments maintain a diversified and robust order pipeline. - The company is confident of sustaining a 25% revenue growth driven by existing and upcoming contracts.